Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27803526 | 0.75 | — | — | |
| SCHEMBL27498102 | 0.71 | — | — | |
| SCHEMBL129187 | 0.70 | — | — | |
| SCHEMBL1548339 | 0.70 | — | — | |
| SCHEMBL8349965 | 0.68 | — | — | |
| SCHEMBL28598425 | 0.67 | ALOX15 (0.36) | ALOX15 | |
| SCHEMBL6028003 | 0.67 | — | — | |
| SCHEMBL28497774 | 0.67 | — | — | |
| Ammonia Solution, Strong SCHEMBL766637 | 0.67 | — | — | |
| Tert-Butanol SCHEMBL15510638 | 0.67 | ALOX15 (0.36) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197661-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-06-20 | — | — | US | disclosed |
| US-20240024249-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20210145755-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | ARBOR PHARMACEUTICALS, LLC | 2021-05-20 | — | — | US | disclosed |
| US-10940117-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | ARBOR PHARMACEUTICALS, LLC (US) | 2021-03-09 | — | — | US | disclosed |
| WO-2020224962-A1 | WATER-SOLUBLE FILMS WITH THREE-DIMENSIONAL TOPOGRAPHY | BASF SE (DE) | 2020-11-12 | — | — | WO | disclosed |
| US-20200246271-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2020-08-06 | — | — | US | disclosed |
| US-10716760-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | ARBOR PHARMACEUTICALS, LLC (US) | 2020-07-21 | — | — | US | disclosed |
| WO-2019238761-A1 | WATER SOLUBLE MULTILAYER FILMS CONTAINING WASH ACTIVE CHEMICALS AND ENZYMES | BASF SE (DE) | 2019-12-19 | — | — | WO | disclosed |
| WO-2019238730-A1 | PROCESS FOR PRODUCING WATER-SOLUBLE CONTAINERS FOR DOSING DETERGENT | BASF SE (DE) | 2019-12-19 | — | — | WO | disclosed |
| US-20170157056-A9 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-1404300-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030091643-A1 | Amorphous mixture of acid sensitive drug and addition polymer; chemical resistance, stability | BEND RESEARCH, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003000235-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| US-6417005-B1 | MEASURING FLUORESCENCE | NOVARTIS AG (CH) | 2002-07-09 | — | — | US | disclosed |
| EP-0894261-A1 | COVALENTLY IMMOBILIZED FLUOROIONOPHORES AS OPTICAL ION SENSORS | Novartis AG (CH) | 1999-02-03 | — | — | EP | disclosed |
| US-5858604-A | PREPARED FROM DIGITAL IMAGE SIGNALS WITH USE OF PRESENSITIZED LITHOGRAPHIC PLATE | KONICA CORPORATION (JP) | 1999-01-12 | — | — | US | disclosed |
| WO-1997039337-A1 | COVALENTLY IMMOBILIZED FLUOROIONOPHORES AS OPTICAL ION SENSORS | NOVARTIS AG (CH) | 1997-10-23 | — | — | WO | disclosed |
| EP-0720057-A1 | ORIGINAL FORM FOR LITHOGRAPHIC PLATE AND PROCESS FOR PREPARING LITHOGRAPHIC PLATE | KONICA CORPORATION (JP) | 1996-07-03 | — | — | EP | disclosed |
| EP-0550844-B1 | Process for obtaining methyl-hydroxyalkyl cellulose ethers | WOLFF WALSRODE AG (DE) | 1996-05-22 | — | — | EP | disclosed |
| EP-0550844-A1 | Process for obtaining methyl-hydroxyalkyl cellulose ethers | Wolff Walsrode Aktiengesellschaft (DE) | 1993-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246271-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | FH, MGMT, BHMT2 | ALOX15 1624/4885ALDH1A1 1454/4885TSHR 4205/4885 |
| US-20210145755-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | FH, MGMT, BHMT2 | ALOX15 1624/4885ALDH1A1 1454/4885TSHR 4205/4885 |
| US-20240024249-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG | FH, MGMT, CYP4F2 | ALOX15 2198/4885ALDH1A1 1240/4885TSHR 4391/4885 |
| US-20170157056-A9 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | FH, MGMT, BHMT2 | ALOX15 1624/4885ALDH1A1 1454/4885TSHR 4205/4885 |
| US-20240197661-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | MGMT, MTHFD2, PHF2 | ALOX15 2263/4885ALDH1A1 2175/4885TSHR 4207/4885 |
| US-20030091643-A1 | Amorphous mixture of acid sensitive drug and addition polymer; chemical resistance, stability | ABCC1, ABCG2, PGD | ALOX15 861/4885ALDH1A1 1657/4885TSHR 4633/4885 |
| US-10940117-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | FH, MGMT, BHMT2 | ALOX15 1624/4885ALDH1A1 1454/4885TSHR 4205/4885 |
| US-10716760-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | FH, MGMT, BHMT2 | ALOX15 1624/4885ALDH1A1 1454/4885TSHR 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.